Alivus Life Sciences Limited
ALIVUS · General/Diversified · NSE
₹1,070
Current Market Price
Fair Value (DCF)
₹1,073
Margin of Safety
+0.3%
Updated just now
YieldIQ Score
36/100
Piotroski F-Score
7/9
Economic Moat
Moderate
Confidence
48%
ROE
17.2%
Debt/Equity
0.00
WACC
9.8%
Market Cap
₹0.13 Lakh Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
22.3%
Return on capital employed
EV / EBITDA
15.9×
Enterprise multiple
Debt / EBITDA
0.1×
Leverage vs earnings
Interest Coverage
272.4×
EBIT covers interest
Current Ratio
4.97×
Short-term liquidity
Asset Turnover
0.74×
Revenue per ₹ of assets
Revenue CAGR (3Y)
—
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹1,070
Bear case
₹627.21
MoS -70.6%
Base case
₹1,073.49
MoS +0.3%
Bull case
₹1,432.14
MoS +25.3%
Ratio Trends
ALIVUS · last 4 annual periods
ROE
17.2%
ROCE
25.0%
Operating Margin
—
Debt / Equity
0.02×
PE
—
EV / EBITDA
—
Historical Financials
ALIVUS · Annual, last 4 years· amounts in ₹Cr unless noted
| Metric | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|
| Revenue | ₹2123 Cr | ₹621 Cr | ₹537 Cr | ₹2340 Cr | +3.3% |
| EBITDA | ₹631 Cr | ₹671 Cr | ₹686 Cr | ₹717 Cr | +4.4% |
| EBIT | ₹593 Cr | ₹198 Cr | ₹130 Cr | — | -39.7% |
| PAT | ₹419 Cr | ₹146 Cr | ₹97.9 Cr | ₹486 Cr | +5.1% |
| EPS (diluted) | ₹35.63 | ₹11.94 | ₹7.97 | — | -39.3% |
| CFO | ₹598 Cr | ₹313 Cr | ₹414 Cr | ₹392 Cr | -13.1% |
| CapEx | — | — | — | ₹-166 Cr | — |
| FCF | — | — | — | ₹225 Cr | +0.0% |
| Total Assets | ₹2471 Cr | ₹2702 Cr | ₹2850 Cr | ₹3411 Cr | +11.3% |
| Total Debt | — | ₹0.0 Cr | ₹0.0 Cr | ₹56.6 Cr | — |
| Shareholders' Equity | — | ₹2138 Cr | ₹2332 Cr | ₹2817 Cr | +9.6% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
ALIVUS vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
| CAPLIPOINT CAPLIPOINT | — | — | Pending | 18.6% | — |
| JUBLPHARMA JUBLPHARMA | — | — | Pending | 13.5% | — |
| COHANCE COHANCE | — | — | Pending | 14.6% | — |
| APLLTD APLLTD | — | — | Pending | 11.2% | — |
| GRANULES GRANULES | — | — | Pending | 13.5% | — |
Click a ticker to view its fair-value analysis.
Dividend History
1 ex-dividend event on file. Source: NSE corporate-actions feed.
Total paid (5Y)
₹5.00/sh
Last payout
2025-09-01
₹5.00
Peak payout
₹5.00
Trailing yield
0.47%
Amounts parsed from NSE subject lines; percent-of-face-value declarations are not converted and shown as missing.
AI Analysis Summary
Model-generated description of metrics. Not investment advice. Alivus Life Sciences Limited (ALIVUS.NS) trades at 1070.00 vs a model fair value of 1073.49, a gap of 0.3%. Piotroski F-score: 7/9. Moat ...
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of ALIVUS →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for ALIVUS →
Compare
Head-to-head with peers
Compare ALIVUS side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse ALIVUSNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.